HOW DRUG CHANNELS HELPS OUR READERS
The $300 billion United States pharmaceutical industry grows ever larger and more complicated by the day. A new generation of specialty drugs is launching, brand-name drugs are facing greater generic competition, channels and payers are consolidating, and the government’s role in the industry keeps increasing.
To remain competitive, it has never been more crucial to master not only the fundamental commercial industry concepts, but also understand the rapidly evolving relationships among the players in the drug channels landscape.
Since 2006, the Drug Channels blog has been helping our thousands of readers make sense of pharmaceutical economics and the drug distribution system. Every week, we deliver timely analysis and provocative, widely regarded opinions on the highly dynamic healthcare system. Drug Channels is the ultimate source for such topics as:
- Pharmacy Economics and Prescription Profits
- Pharmaceutical reimbursement
- Business strategies of key market participants, including manufacturers, pharmacies, pharmacy benefit managers (PBMs), third-party payers, and wholesalers
- Industry evolution and trends
- The fast-growing specialty drug market
- Health care reform and policy
- Legal aspects of the pharmaceutical supply chain
ADAM J. FEIN, PH.D.
Drug Channels was created and is written by Adam J. Fein, Ph.D., one of the country’s foremost experts on pharmaceutical economics and channel strategy. The president of Pembroke Consulting, Inc., and CEO of Drug Channels Institute, Dr. Fein consults with clients in the pharmaceutical and healthcare industries. Eleven of the 15 largest biopharmaceutical manufacturers have relied upon Dr. Fein for his experience, analyses, and insights to help them improve profitability and make better strategic decisions. Click here to read more about Dr. Fein’s industry presence.
Dr. Fein excels at unlocking and explaining complex business and economic issues with humor and an accessible, straightforward style, making Drug Channels a popular and authoritative destination for both industry insiders and outsiders. Drug Channels has been cited in such media outlets as The Wall Street Journal and Drug Benefit News, in academic research papers, and across other industry websites.
A leader in the pharmaceutical economics blogosphere, Drug Channels has a loyal following of engaged readers. Drug Channels attracts a large, unique, diverse audience throughout the pharmaceutical and healthcare industries.
Our readers’ backgrounds reflect the many diverse topics that Drug Channels reports and analyzes. We offer free subscriptions via email, RSS feed, or Twitter. As of February 2013, Drug Channels has nearly 7,000 subscribers via these methods. All articles are also shared with the more than 1,000 people on Dr. Fein’s personal LinkedIn account. Many key healthcare industries are represented in our readership.
View of a list of companies that visited Drug Channels.
HOW DRUG CHANNELS HELPS OUR READERS
“Drug Channels is one of my must-follow resources for knowledgeable insight into events that are shaping the future of our industry. Dr. Fein's ability to find the real meaning behind the headlines is refreshing and invaluable.”SITE TRAFFIC
Bill Martin, Group Vice President, Specialty Business Development, Accredo Health Group, Inc.
“Drug Channels is a terrific (and entertaining) resource to stay up to date on complex issues related to the pharmaceutical channel. The mix of pop culture references with deep insight into current events makes the articles a must read.”
Keith Wagner, Pharm.D., MBA, Director, Trade/Specialty Accounts, Lilly USA
“Great informative and timely information with a wit and humor that reminds us that serious issues all need to be tempered with a sense of levity.”
Scott A. Miller, PharmD, Director, Clinical Strategic Initiatives, Walgreens
“Drug Channels brings unique insight on a rapidly evolving health care marketplace by challenging us to think critically, and to look for the forest beyond the trees.”
Dave D'Altorio, Senior Vice President, Corporate Development, MedImpact
"Drug Channels is my best source of current, up-to-date information about current events affecting pharmacies, wholesalers, and PBMs. I constantly use the information in my teaching, research, and consulting."
Norman V. Carroll, R.Ph, Ph.D., Professor of Pharmacoeconomics and Health Outcomes, School of Pharmacy, Virginia Commonwealth University
Drug Channels' site traffic is growing by 25% to 30% per year. According to Media Rating Council certified traffic data, there were more than 60,000 net monthly page views in March 2013. The chart below shows the growth in page views and unique visits as recorded by Statcounter, our web traffic provider.
Click here to view current summary web traffic data for Drug Channels.
Learn about advertising on Drug Channels and connecting with our community.